US awards $3.4 million for S. aureus vaccine

Wednesday 5 May 2010

The US National Institutes of Health have awarded $3.4 million to GlycoVaxyn AG of Switzerland and a researcher at the Harvard Medical School to carry out preclinical work on a new S. aureus vaccine for hospital-acquired infections.

 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland